Liproxstatin-1 as Mechanism-Validation Tool for Ferroptosis Inhibition
🧪 Overview
Liproxstatin-1 (Lip-1) inhibits ferroptosis upstream of GPX4 by blocking lipoxygenase-mediated lipid peroxidation, preserving endothelial tight junction mRNA stability. While well-characterized in research, Lip-1 is a research tool without clinical formulation, characterized by metabolic instability and poor solubility. Its primary value is as a comparator to establish causality: if direct ferroptosis inhibition fails to protect BBB, the therapeutic thesis weakens. The HDAC4 mechanism is speculative and not causally validated.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["ALOX12/15 12/15-lipoxygenase / HDAC4 axis<br/>Hypothesis Target"]
B["Ferroptosis<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["Neurodegeneration<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ALOX12
No curated PDB or AlphaFold mapping for ALOX12 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for ALOX12/15 (12/15-lipoxygenase) / HDAC4 axis from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ALOX12.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary mouse brain microvascular endothelial cells (BMECs) are treated with Liproxstatin-1 (100 nM) during OGD/R (oxygen-glucose deprivation/reperfusion) injury, THEN the mRNA expression of tight | Liproxstatin-1 preserves ≥80% of tight junction mRNA (CLDN5, OCLN, TJP1) expression compared to vehicle control under OGD/R conditions | — no observation — | pending | 0.65 |
| IF HDAC4 is genetically knocked down via siRNA in primary mouse BMECs, THEN Liproxstatin-1 (100 nM) will fail to preserve tight junction mRNA stability under OGD/R conditions, demonstrating HDAC4 as a | HDAC4 knockdown abolishes Liproxstatin-1's protective effect on tight junction mRNA (CLDN5, OCLN, TJP1) stability under OGD/R | — no observation — | pending | 0.45 |
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |